Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...

NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...

A new study by Phoenix's Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered ...

A 37-year-old woman presents as a new patient. Her past medical history consists of depression, fatigue, anxiety, insomnia ...

Calgary neurologist Dr. Serena Orr spent her career researching migraine attacks and trying to bring patients relief from the painful symptoms.

TMJ issues rarely begin in the jaw itself. The small stabilizing muscles under the skull and upper neck share a nerve network ...

Clinicians may fail to recognize common side effects of drugs like gabapentin - which are frequently prescribed for nerve pain - leading them to prescribe unnecessary medications that cause yet more ...

Gathering together with family to celebrate and give thanks reminds us to practice the art of Gratitude. There are many who ...

Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Friday, December 05 based on AAII’s Stock Grades.

Plexiform neurofibromas (PNF) are benign, often infiltrative tumours of the peripheral nerve sheath classically linked to ...